# Use of SGLT2i in noHCM With HFpEF

> **NCT06401343** · PHASE4 · RECRUITING · sponsor: **China National Center for Cardiovascular Diseases** · enrollment: 94 (estimated)

## Conditions studied

- Hypertrophic Cardiomyopathy
- Heart Failure With Preserved Ejection Fraction

## Interventions

- **DRUG:** Empagliflozin 10 MG

## Key facts

- **NCT ID:** NCT06401343
- **Lead sponsor:** China National Center for Cardiovascular Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-01
- **Primary completion:** 2024-08-01
- **Final completion:** 2025-08-01
- **Target enrollment:** 94 (ESTIMATED)
- **Last updated:** 2024-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06401343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06401343, "Use of SGLT2i in noHCM With HFpEF". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT06401343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*